Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

A method of treating early-stage HER2-positive breast cancer in a patient comprising administering Pertuzumab, Trastuzumab, and carboplatin-based chemotherapy to the patient with the early-stage breast cancer.

A method of treating a HER2-positive cancer patient comprising administering to the patient an initial dose of 840 mg of Pertuzumab followed every 3 weeks thereafter by a dose of 420 mg of Pertuzumab, and further comprising re-administering an 840 mg dose of Pertuzumab to the patient if the time between two sequential 420 mg doses is 6 weeks or more.

A method of combining two HER2 antibodies to treat HER2-positive breast cancer without increasing cardiac toxicity in a HER2-positive breast cancer patient with a left ventricular ejection fraction (LVEF) of ≤50% pre-treatment, comprising administering Pertuzumab, Trastuzumab, and chemotherapy to the patient, and measuring cardiac toxicity in the patient for incidence of symptomatic left ventricular systolic dysfunction (LVSD), congestive heart failure (CHF), or decrease in left ventricular ejection fraction (LVEF), wherein the cardiac toxicity is not increased compared to cardiac toxicity in a patient treated with Trastuzumab and the chemotherapy.

A method of treating a patient with HER2-positive breast cancer comprising administering Pertuzumab, Trastuzumab, and chemotherapy to the patient, and measuring left ventricular ejection fraction (LVEF) in the patient and withholding treatment with pertuzumab and trasutuzmab for at least 3 weeks if the patient has a drop in LVEF to less than 40%, or a LVEF of 40% to 45% with a 10% or greater absolute decrease below pre-treatment value.